TP53 and cancer: Concurrently, mutant TP53 may acquire novel oncogenic properties, such as activation of the PI3K-Akt signaling pathway drives metabolic reprogramming by upregulating aerobic glycolysis (the Warburg effect), thereby supplying cancer cells with ATP and biosynthetic precursors to fuel their uncontrolled proliferation-a process further modulated by miRNA networks [23].